FDA Panel Advice To Limit Aquavan Administration Would Also Limit Market
Executive Summary
If FDA takes an advisory panel's advice to limit approval of MGI Pharma's Aquavan (fospropofol) to administration only by trained anesthesiologists, the market for the sedative - which would then compete directly with its active moiety, propofol - would be substantially limited
You may also be interested in...
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
Company was hoping to position Lusedra as an anesthetic that did not require the presence of an anesthesiologist.
Eisai’s Aquavan “not approvable”
Eisai receives a "not approvable" action letter for its sedative fospropofol, the firm says July 25. An FDA advisory committee recommended approval of fospropofol for patients undergoing diagnostic or therapeutic procedures in May, but suggested limiting it to administration by trained anesthesiologists, thereby obviating any marketing advantage over its active moiety, propofol (1"The Pink Sheet," May 12, 2008, p. 13). The sponsor had hoped that the prodrug would have a sufficiently distinct safety profile to allow for general administration
Eisai’s Aquavan “not approvable”
Eisai receives a "not approvable" action letter for its sedative fospropofol, the firm says July 25. An FDA advisory committee recommended approval of fospropofol for patients undergoing diagnostic or therapeutic procedures in May, but suggested limiting it to administration by trained anesthesiologists, thereby obviating any marketing advantage over its active moiety, propofol (1"The Pink Sheet," May 12, 2008, p. 13). The sponsor had hoped that the prodrug would have a sufficiently distinct safety profile to allow for general administration